Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 13/20 | 0.44 |
| ▸ | CDK1 | P06493 | 13/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 13/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 13/20 | 0.44 |
| ▸ | GSK3A | P49840 | 11/20 | 0.44 |
| ▸ | GSK3B | P49841 | 11/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288173 | 0.88 | ACLY (0.38) | MEN1KMT2APOLBACLYNPSR1 | |
| SCHEMBL6279221 | 0.87 | RIPK1 (0.52) | CCNB2CDK1CCNB1CCNB3MAPK1 | |
| SCHEMBL6285019 | 0.86 | ACLY (0.36) | MEN1KMT2APOLBACLYNPSR1 | |
| SCHEMBL6288131 | 0.84 | IRAK4 (0.40) | MEN1KMT2APOLBACLYNPSR1 | |
| SCHEMBL6288150 | 0.84 | ACLY (0.37) | MEN1KMT2APOLBACLYNPSR1 | |
| SCHEMBL6288129 | 0.83 | MAPT (0.41) | GSK3BMEN1KMT2AACLYNPSR1 | |
| SCHEMBL6286958 | 0.83 | F3 (0.43) | GSK3BMEN1KMT2APOLBACLY | |
| SCHEMBL6288186 | 0.83 | IRAK4 (0.38) | MEN1KMT2APOLBACLYNPSR1 | |
| SCHEMBL6285928 | 0.83 | KMT2A (0.39) | GSK3BMEN1KMT2APOLBACLY | |
| SCHEMBL6286254 | 0.83 | GSK3B (0.44) | GSK3BMEN1KMT2APOLBACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | PICARD JOSEPH ARMAND (US) | 2004-01-22 | — | — | US | claimed |
| EP-1294718-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001096336-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | claimed |
| US-6943174-B2 | 6,5-Fused bicyclic heterocycles | WARNER-LAMBERT COMPANY (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | PICARD JOSEPH ARMAND (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1294718-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001096336-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014759-A1 | 6,5-Fused bicyclic heterocycles | ALOX15, ALOX5, ALOX15B | CCNB2 2282/4885CDK1 1374/4885CCNB1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.